References
- 1. Carrasco-Hernandez R, Jácome R, López Vidal Y, Ponce de León S. Are RNAviruses candidate agents for the next global pandemic? A review. ILAR J. 2017; 58:343-58.10.1093/ilar/ilx026710857128985316
- 2. Enard D, Petrov DA. Ancient RNA virus epidemics through the lens of recent adaptation in human genomes. Philos Trans R Soc Lond B Biol Sci. 2020; 375:20190575.10.1098/rstb.2019.0575770280333012231
- 3. Duffy S. Why are RNA virus mutation rates so damn high? PLOS Biol. 2018;16: e3000003.10.1371/journal.pbio.3000003610725330102691
- 4. Zhao Z, Bourne PE. Structural insights into the binding modes of viral RNA-dependent RNA polymerases using a function-site interaction fingerprint method for RNA virus drug discovery. J Proteome Res. 2020; 19:4698-705.10.1021/acs.jproteome.0c00623764097632946692
- 5. Yashvardhini N, Jha DK, Bhattacharya S. Identification and characterization of mutations in the SARS-CoV-2 RNA-dependent RNA polymerase as a promising antiviral therapeutic target. Arch Microbiol. 2021; 203:5463-73.10.1007/s00203-021-02527-9837412134410443
- 6. Frick DN. Helicases as antiviral drug targets. Drug News Perspect. 2003; 16:355-62.10.1358/dnp.2003.16.6.829307357168312973446
- 7. Shyr ZA, Gorshkov K, Chen CZ, Zheng W. Drug discovery strategies for SARS-CoV-2. J Pharmacol Exp Ther. 2020; 375:127-38.10.1124/jpet.120.000123756930632723801
- 8. Jankowsky E. RNA helicases at work: binding and rearranging. Trends Biochem Sci. 2011; 36:19-29.10.1016/j.tibs.2010.07.008301721220813532
- 9. Briguglio I, Piras S, Corona P, Carta A. Inhibition of RNA helicases of ssRNA+ virus belonging to Flaviviridae, Coronaviridae and Picornaviridae families. Int J Med Chem. 2011;2011:213135.10.1155/2011/213135497065027516903
- 10. Halim SA, Khan S, Khan A, Wadood A, Mabood F, Hussain J, Et al. Targeting Dengue Virus NS-3 Helicase by Ligand based Pharmacophore Modeling and Structure based Virtual Screening. Front Chem. 2017; 5:88.10.3389/fchem.2017.00088567165029164104
- 11. Kadaré G, Haenni AL. Virus-encoded RNA helicases. J Virol. 1997; 71:2583-90.10.1128/jvi.71.4.2583-2590.19971913789060609
- 12. El-Sayed AF, Mohammed AT, Hamed W, Abdelmalek S. Repurposing of available antiviral drugs against SARSCoV-2 by targeting crucial replication machinery proteins: a molecular docking study. Egypt Pharm J. 2021;20 :371-92.
- 13. Faheem M, Singh VK, Srivastava A. Recent insights of SARS-CoV-2 potential inhibitors. Biomed Biotechnol Res J (BBRJ). 2022; 6:21-32.10.4103/bbrj.bbrj_229_21
- 14. Satpathy R. In silico modeling and docking study of potential helicase (nonstructural proteins) inhibitors of novel coronavirus 2019 (severe acute respiratory syndrome coronavirus 2). Biomed Biotechnol Res J. 2020;4:330-6.10.4103/bbrj.bbrj_149_20
- 15. Shu T, Huang M, Wu D, Ren Y, Zhang X, Han Y et al. SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virol Sin. 2020; 35:321-9.10.1007/s12250-020-00242-1727183132500504
- 16. White MA, Lin W, Cheng X. Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase. J Phys Chem Lett. 2020; 11:9144-51.10.1021/acs.jpclett.0c02421757130633052685
- 17. Abidi SH, Almansour NM, Amerzhanov D, Allemailem KS, Rafaqat W, Ibrahim MAA et al. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARSCoV-2 helicase. Sci Rep. 2021;11:1:10290.10.1038/s41598-021-89724-0811968933986405
- 18. Kwong AD, Rao BG, Jeang KT. Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov. 2005; 4:845-53.10.1038/nrd1853709719116184083
- 19. Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol Sci. 2014; 35:86-102.10.1016/j.tips.2013.11.006711280424439476
- 20. Hanson AM, Hernandez JJ, Shadrick WR, Frick DN. Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase. Methods Enzymology2012; 511:463-8310.1016/B978-0-12-396546-2.00021-8357168222713333
- 21. Shadrick WR, Ndjomou J, Kolli R, Mukherjee S, Hanson AM, Frick DN. Discovering new medicines targeting helicases: challenges and recent progress. J Biomol Screen. 2013; 18:761-81.10.1177/1087057113482586442723323536547
- 22. Parvez MK, Subbarao N. Molecular analysis and modeling of hepatitis E virus helicase and identification of novel inhibitors by virtual screening. Biomed Res Int. 2018;2018:5753804.
- 23. Pattnaik GP, Chakraborty H. Entry inhibitors: efficient means to block viral infection. J Membr Biol. 2020; 253:425-44.10.1007/s00232-020-00136-z745644732862236
- 24. Satpathy R, Konkimalla VSB, Ratha J. Dehalobase: a database of dehalogenase and other allied enzymes. Int Jrnl Appl Res Info Tech and Comp. 2015; 6:33-7.10.5958/0975-8089.2015.00004.4
- 25. Letkowski J. Doing database design with MySQL. J Technol Res. 2015; 6:1.
- 26. Welling L, Thomson L. PHP and MySQL Web development. Sams Publishing; 2003.
- 27. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today Technol. 2004; 1:337-41.10.1016/j.ddtec.2004.11.00724981612
- 28. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46: W257-63.10.1093/nar/gky318603101129718510
- 29. Satpathy R. Application of molecular docking methods on endocrine disrupting chemicals: a review. J Appl Biotechnol Rep. 2020; 7:74-80.
- 30. Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019; 7:83-9.10.1007/s40484-019-0172-y
- 31. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comp Chem. 2010; 31:455-61.
- 32. Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ et al. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49: W530-4.10.1093/nar/gkab294826272033950214
- 33. Newman JA, Douangamath A, Yadzani S, Yosaatmadja Y, Aimon A, Brandão-Neto J et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat Commun. 2021; 12:484810.1038/s41467-021-25166-6835806134381037
- 34. Jia Z, Yan L, Ren Z, Wu L, Wang J, Guo J et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 2019; 47:6538-50.10.1093/nar/gkz409661480231131400
- 35. Hao W, Wojdyla JA, Zhao R, Han R, Das R, Zlatev I et al. Crystal structure of Middle East respiratory syndrome coronavirus helicase. PLOS Pathog. 2017;13:e1006474.10.1371/journal.ppat.1006474550169428651017
- 36. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug MetabToxicol. 2013; 9:763-75.10.1517/17425255.2013.79128223590413
- 37. Das L, Dutta P. SGLT2 inhibition and COVID-19: the road not taken. Eur J Clin Investig. 2020:e13339.10.1111/eci.13339740451532648935
- 38. Koufakis T, Pavlidis AN, Metallidis S, Kotsa K. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases. Int J Clin Pharm. 2021;43:764-7.10.1007/s11096-021-01256-9794252033751323
- 39. Cannalire R, Cerchia C, Beccari AR, Di Leva FS, Summa V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J Med Chem. 2020;65:2716-46.10.1021/acs.jmedchem.0c01140768804933186044
- 40. Khater I, Nassar A. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease. Biochem Biophys Rep. 2021;27:101032.10.1016/j.bbrep.2021.101032817349534099985
- 41. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766-88.10.1016/j.apsb.2020.02.008710255032292689
- 42. Lau EY, Negrete OA, Bennett WFD, Bennion BJ, Borucki M, Bourguet F et al. Discovery of small-molecule inhibitors of SARS-CoV-2 proteins using a computational and experimental pipeline. Front Mol Biosci. 2021;8:678701.10.3389/fmolb.2021.678701831500434327214
- 43. SOYLU M, ÖZBEK EN, YetİkAnacak GY. Drug repur-posing in the treatment of COVID-19. Bezmiâlem Sci. 2020;8:84-93.10.14235/bas.galenos.2020.4925
- 44. Muhammed Y. Molecular targets for COVID-19 drug development: enlightening Nigerians about the pandemic and future treatment. Biosaf Health. 2020;2:210-6.10.1016/j.bsheal.2020.07.002734365032838282
- 45. Delre P, Caporuscio F, Saviano M, Mangiatordi GF. Repur-posing known drugs as covalent and non-covalent inhibitors of the SARS-CoV-2 papain-like protease. Front Chem. 2020;8:594009.10.3389/fchem.2020.594009770129033304884
- 46. Mahmoudi S, Dehkordi MM, Asgarshamsi MH. The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. Biophysical Chemistry. 2022.10.1016/j.bpc.2022.106824909507135728510
- 47. Khan AA, Dutta T, Mondal P, Mandal M, Chowdhury SK, Ahmed M et al. Novel coronavirus Disease (COVID-19): an extensive study on evolution, global health, drug targets and vaccines. Int J Clin Virol. 2021;5:054-69.10.29328/journal.ijcv.1001036
- 48. Unni S, Aouti S, Thiyagarajan S, Padmanabhan B. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. J Biosci. 2020;45:1-20.10.1007/s12038-020-00102-w
- 49. Fallah MS, Bayati M, Najafi A, Behmard E, Javad S. Molecular docking investigation of antiviral herbal compounds as potential inhibitors of sars-cov-2 spike receptor. Biointerface res. J Appl Chem. 2021;11:12916-24.
- 50. Ugwueze CV, Ezeokpo BC, Nnolim BI, Agim EA, Anikpo NC, Onyekachi KE. COVID-19 and diabetes mellitus: the link and clinical implications. Dubai Diabetes Endocrinol J. 2020;26:69-77.10.1159/000511354